

AJOONI BIOTECH LIMITED

Regd. Office: D-118, Industrial Area, Phase VII, Mohali-160055 (Pb.) Phone: 0172-5020758-69 Website: <u>www.ajoonibiotech.com</u> E-mail: <u>ajooni.biotech@gmail.com</u> / <u>info@ajoonibiotech.com</u>

CIN: L85190PB2010PLC040162

November 13, 2024

To, National Stock Exchange of India Ltd Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (E) Mumbai - 400051

Subject: Outcome of the Board Meeting held on Wednesday, November 13, 2024, pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015.

SYMBOL: AJOONI

Dear Sir/Madam,

With reference to the above captioned subject, we wish to inform you that the Board of Directors of the Company at their meeting held on Wednesday, November 13, 2024 at 02.30 p.m. concluded at 03.30 p.m. Following transactions were considered and approved:

- 1. The un-audited Financial Results for the quarter and half year ended September 30, 2024.
- 2. Limited Review Report for the quarter and half year ended September 30, 2024.

You are requested to kindly take the same on your record and acknowledge receipt.

Thanking You, Yours Truly, For Ajooni Biotech Limited

Jasjot Singh Managing Director DIN: 01937631

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED Automation ANTECULARS QUANCISK ENDED Transition Automation Indel automation automation Automation Automation Automation Indel automation automation automation automation Automation Automation Indel automation 2,573.41 2,566.85 1,947.99 5,132.99 4,048.26 2,043.03 Indel 2,303.40 2,566.85 1,947.99 5,132.99 4,048.26 8,201.39 Indel 2,303.40 2,566.85 1,947.99 5,132.99 4,048.26 8,201.39 Indel 2,303.40 2,566.85 1,947.99 5,132.99 4,048.36 8,201.39 Indel 2,303.40 2,303.40 2,304.97 3,313.49 4,043.48 8,204.49 8,304.46 Indel 2,304.50 1,504.50 1,512.89 4,045.50 5,560.56 5,560.56 5,560.56 5,560.56 5,560.56 5,560.56 5,560.56 5,560.56			CIN: L8519	JOONI BIOTECH LIMITED : L85190PB2010PLC040162	LIMITED PLC040162			
(UARTER ENDED CUARTER ENDED sunsation anonation trained instant trained instant trained instant trained instant trained instant trained instant traination trained instant traination		STATEMENT OF STANDALONE FIN	VANCIAL RESULT	S FOR THE Q	JARTER END	ED 30TH SEI	TEMBER 2024	l (In Lakhs)
RUNA 2004 SOME 2004 SOME RULA SOME RULA SOME RULA SOME RULA SOME RULA RULA ALLER RULA ALLER <th></th> <th>PARTICULARS</th> <th></th> <th>QUARTER I</th> <th>INDED</th> <th></th> <th></th> <th>Year Ended</th>		PARTICULARS		QUARTER I	INDED			Year Ended
acconance acconance acconance 2,572.44 2,565.85 1,947.99 5,138.29 4,048.26 8 30.96 3.67 29,00 34.63 34.63 36.82 8 30.96 3.67 29,00 34.63 34.63 36.82 8 2,003.40 2,569.52 1,976.99 5,172.92 4,048.36 8 2,247.25 2,248.65 1,743 9 4,95.90 3,645.60 6, 703.11 5.990 15.02 19,19 27.73 3,645.60 6, 703.11 5.723 2,143.80 4,495.90 3,645.60 6, 703.11 5.723 2,13.51 2,002 32.57 7,7 5.990 15.02 19,19 20,92 7,7 7,7 61.81 65.60 5,133.75 17,002 7,7 7 7,252 2,132.57 1,201 7,7 7 7,252 2,233.35 1,201 7,7 <td< th=""><th></th><th></th><th>30.09.2024</th><th>30.06.2024</th><th>207'60'02</th><th>Period Ended (UnAndited)</th><th>Period Ended (UnAudited)</th><th>Auanea) 31.03.2024</th></td<>			30.09.2024	30.06.2024	207'60'02	Period Ended (UnAndited)	Period Ended (UnAudited)	Auanea) 31.03.2024
2,572,44 2,563,55 1,947,99 5,138,29 4,048,26 8 30,96 3,67 29,00 34,63 36,22 8 2,603,40 2,569,52 1,976,99 5,172,92 4,084,48 8 2,247,25 2,248,65 1,743,89 4,495,90 3,646,60 6, 2,247,25 2,248,65 1,743,89 4,495,90 3,646,60 6, 7,91 70,31 57,23 21,019 20,92,97 7, 7,91 5,50 22,33 2,506,92 1,53,91 40,471 7,93 15,02 19,109 20,92 32,57 7,94 5,506,92 1,524,91 5,009,85 3992,97 7, 7,94 2,566,92 1,524,91 5,009,85 3992,97 7, 168,50 165,29 1,522,91 5,009,85 3992,97 7, 168,50 165,29 1,522,91 5,009,85 3992,97 7, 168,50 165,29 1,522,91 5,009,85 3992,97 7, 168,50 1,522,91 5,008 1,42,07 91,51 7, 168,50 1,11 0,58 1,92,69 1,550 1,550 1,550 19,51	-	Income				30.09.2024	30.09.2023	
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		Revenue from operations	0 577 AA	20 373 6	1 047 00	00 001 2		
2,603.40 2,569.52 1,773 3,0.22 3,0.22 3,0.24 8 2,247.25 2,248.65 1,743.89 4,495.90 5,172.92 4,084.48 8 8 2,247.25 2,248.65 1,743.89 4,495.90 5,172.92 4,084.48 8 8 2,391 5,90 15,02 15,02 15,02 104.71 (3.18) 2,590 15,02 15,02 19,19 20,92 3,557 6 2,590 15,02 21,34 44.88 42.25 7 7 168.50 165.29 73.51 333.79 170.02 7 7 168.50 165.20 1,520 1,520 142.07 91.51 7 10x 79.47 62.60 52.08 142.07 91.51 7 10x 79.441 62.60 52.08 142.07 91.51 7 10x 79.441 62.60 52.08 142.07 91.51 7		Other income	11:210,2	2 67	96.146.1	0,158.29	4,048.26	8,011.46
-10000 -100000 -100000 -100000 -100000 -100000 -100000 -1000000 -1000000 -10000000 -100000000 $-1000000000000000000000000000000000000$		Total income from operations	2.603.40	70.6	1 076 00	24.03	30.22	219.33
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$					aren ris	76.71160	4,004.40	8,230.79
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		Cost of Material Consumed	2,247.25	2,248.65	1,743.89	4.495.90	3.646.60	DE 986 A
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		Change In Inventories	9.41	(1.64)	15.90	77.7	(3.18)	48.65
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		Employee benefit expenses	70.31	57.28	51.08	127.59	104.71	180.05
22.56 22.32 21.34 44.88 42.25 168.50 165.29 73.51 333.79 170.02 5 2,523.93 2,506.92 1,924.91 5,030.85 3,992.97 7,9 2,523.93 2,506.92 1,924.91 5,030.85 3,992.97 7,9 1 79.47 62.60 52.08 142.07 91.51 2 79.47 62.60 52.08 142.07 91.51 2 79.47 62.60 52.08 142.07 91.51 2 19.07 15.20 12.50 12.50 12.50 12.50 12.50 -1.11 0.58 0.89 1.65 (1.65) 1 2 61.51 46.82 40.47 127.92 80.66 2 2 54.14 54.14 (162.77) 11.55 16.51 1 1 dysen 15.55 3,444.87 1,752.27 3,444.87 1,752.27 1,752.27 1,752.27		Finance costs	5.90	15.02	19.19	20.92	32.57	69.001
168.50 165.29 73.51 333.79 170.02 5 $2,523.33$ $2,506.92$ $1,924.91$ $5,030.85$ 392.97 7.9 79.47 62.60 52.08 142.07 91.51 2 79.47 62.60 52.08 142.07 91.51 2 79.47 62.60 52.08 142.07 91.51 2 79.47 15.20 12.50 12.50 12.50 2 19.07 15.20 12.50 12.50 12.50 2 -1.11 0.58 0.89 1.65 (1.65) 2 -1.11 0.58 0.89 1.65 (1.65) 2 61.51 46.82 40.47 127.92 80.66 2 54.14 (162.77) 54.14 (162.77) $(11$ $dyster 115.65 46.47 127.92 80.66 2 dyster 54.14 $		Depreciation and amortization expenses	22.56	22.32	21.34	44.88	42.25	67.73
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		Payment to NSE					24.4	21.10
2,523.93 $2,506.92$ $1,924.91$ $5,030.85$ $3,992.97$ 7 d tax 79.47 62.60 52.08 142.07 91.51 7 r 79.47 62.60 52.08 142.07 91.51 7 r 79.47 62.60 52.08 142.07 91.51 7 r 19.07 15.20 12.50 12.50 12.50 12.50 -1.11 0.58 0.89 12.50 12.50 12.50 12.50 -1.11 0.58 0.89 142.07 91.51 7 61.51 46.82 40.47 127.92 80.66 6 61.51 46.82 40.47 127.92 80.66 6 61.75 54.14 162.77 (162.77) $(1$ 61.98 54.14 162.79 (162.77) $(1$ 61.98 $1.752.27$ $3.444.87$ $1.7722.27$ 1.7	- 1	Other expenses	168.50	165.29	73.51	333.79	170.02	573 03
d tax 79.47 62.60 52.08 142.07 91.51 2 7 79.47 62.60 52.08 142.07 91.51 2 1 19.07 15.20 12.50 12.50 12.50 12.50 1 19.07 15.20 12.50 12.50 12.50 2 1 0.58 0.89 1.65 (1.65) 2 2 1 111 0.58 0.89 1.65 (1.65) 2 54.14 61.51 46.82 40.47 127.92 80.66 2 54.14 54.14 (162.77) (1) 1 1 diyear 115.65 46.82 40.47 127.92 80.66 2 diyear 115.65 46.82 40.47 127.92 80.66 2 fthe 54.14 (162.77) (1) 1 1 1 1	18		2,523.93	2,506.92	1,924.91	5.030.85	3.992.97	7.931 18
79.47 62.60 52.08 142.07 91.51 2 19.07 19.07 15.20 12.50 12.50 12.50 2 -1.11 0.58 0.89 1.65 (1.65) 2 -1.11 0.58 0.89 1.65 (1.65) 2 -1.11 0.58 0.89 1.65 (1.65) 2 61.51 46.82 40.47 127.92 80.66 2 54.14 - 54.14 (162.77) (1 d/year 115.65 46.82 40.47 127.92 80.66 2 d/year 54.14 - 54.14 (162.77) (1 d/year 115.65 46.82 40.47 182.06 (82.11) 1 f the 54.14 1,752.27 3,444.87 1,752.27 1,75 1,75	-		79.47	62.60	52.08	142.07	91.51	200 61
79.47 62.60 52.08 142.07 91.51 2 19.07 15.20 12.50 12.50 12.50 12.50 -1.11 0.58 0.89 1.65 (1.65) 2 -1.11 0.58 0.89 1.65 (1.65) 2 -1.11 0.58 0.89 1.65 (1.65) 2 -1.11 0.58 0.89 1.65 2 2 54.14 54.14 127.92 80.66 2 54.14 54.14 54.14 (62.77) (1) dysar 115.65 46.82 40.47 137.92 80.66 2 dysar 54.14 54.14 (62.77) (1) 1) dysar 115.65 46.82 40.47 182.06 (82.11) 1) fthe 54.14 1,752.27 3,444.87 1,752.27 1,752.27 1,752.27 1,752.27 1,752.27 1,752.27 1,752.27 1,752.27 1,752.27 1,752.27 1,752.27 1,752.27 1,752.27 1,7752.27 1,7752.27 1,7752.	21	Exceptional items						TOWNER
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	20	Profit/(Loss) before tax	79.47	62.60	52.08	142.07	91 51	100 61
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	-1	Tax expenses					A.V.4./	Incom
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$		a) Current tax	19.07	15.20	12.50	12 50	12 50	01 SN
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		b) Deferred tax	-1.11	0.58	0.80	1 65	11 661	00.10
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		b) Mat Credit			10.0	CU.1	((01)	(10.4)
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	-	Net Profit/(Loss) for the period/year	61.51	46.82	LFUF	137.03	22 00	61 J 10
loss: 54.14 54.14 (162.77) Total other comprehensive income 54.14 (162.77) Total comprehensive income for the period/year 54.14 (162.77) Total comprehensive income for the period/year 115.65 46.82 40.47 182.06 (82.11) Paid-up equity share capital (face value of the state of the indicated) $33,444.87$ $1,752.27$ $3,444.87$ $1,752.27$	=	Other comprehensive income (net of tax)					00.00	71.012
Total ather comprehensive income 54.14 54.14 (162.77) Total comprehensive income for the period/year 54.14 (162.77) Total comprehensive income for the period/year 115.65 46.82 40.47 182.06 (82.11) Paid-up equity share capital (face value of the shall be indicated) 3,444.87 1,752.27 3,444.87 1,752.27 1	-	loss:	54.14			54.14	(162.77)	(103.22)
Total other comprehensive income 54.14 (162.77) Total comprehensive income for the period/year 115.65 46.82 40.47 182.06 (82.11) Paid-up equity share capital (face value of the shall be indicated) 3,444.87 1,752.27 3,444.87 1,752.27 1	1							(marrow)
Total comprehensive income for the period/year 115.65 46.82 40.47 182.06 (82.11) Paid-up equity share capital (face value of the share shall be indicated) 3,444.87 1,752.27 3,444.87 1,752.27 1	T	Total other comprehensive income	54.14			54.14	(162.77)	(103.22)
Paid-up equity share capital (face value of the 3,000,3,444.87 1,752.27 3,444.87 1,752.27 1,	1846	Total comprehensive income for the period/year (VII+VIII)	115.65	46.82	40.47	182.06	(82.11)	112 00
-		Paid-up equity share capital (face value of the share shall be indicated)	V Z	3,444.87	1,752.27	3,444.87	1.752.27	1.752.27
			OHALI *	-35				

		2,518.51		30 0	C4.0	0.25
		60.206,2		0.46	2 12	0.40
	2 167 ET	10.101.6		0.04	0.04	40'0
	7.337.55		1000	0.23	0.72	0.4.0
	5.104.74		000	0.05	0.03	22.2
	5,167.57		0.04	40.0	0.04	
	we were equity (excluding revaluation reserve)	of Rs.10/- cach)*				
)ther addity favoluding	umning (excinding	EPS in Rs. (Face Value of Rs.10/- each)*	-Basic	Direct	Danna-	
XI		XII E				Notes:

ÿ.

.



AJOONI BIOTECH LIMITED

Regd. Office : D-118, Industrial Area, Phase-VII, Mohali-160055 (Pb.) Phone : 0172-5020758-69 Website : www.ajoonibiotech.com E-mail : ajooni.biotech@gmail.com / info@ajoonibiotech.com CIN: L85190PB2010PLC040162

CAS	H FLOW STATEMENT FOR THE HALF YEAR EN	DED 30TH	SEPTEM	BER 2024
CIRC				Amount in Rs. (Lakhs)
"A" (1)	CASH FLOW FROM OPERATING ACTIVITIES			
	Profit/(Loss) Before Tax			61.51
	Adjustments for:			
	Depreciation & Amortization	22.56		
	Interest & Finance Charges	5.90		
	Interest Income	-30.86	(2.40)	
	Operating Profit before Working Capital Changes			59.11
	Adjustments for:			
	Decrease/(Increase) in Receivables	-1,037.49		
	Decrease/(Increase) in Inventories	-159.44		
	Decrease/(Increase) in Loans and Other Advances	-1,035.46		
	Decrease/(Increase) in Other Current Assets	-18.39		
1	Increase/(Decrease) in Trade Payables	-158.45		
2	Increase/(Decrease) in Other Current Liabilities	59.09	-2,350.13	
	Cash generated from operations			(2,291.02)
	Tax paid prev year			
	Net Cash flow from Operating activities			(2,291.02)
	(2) CASH FLOW FROM INVESTING ACTIVITIES			
	Purchase of Tangible Assets/ Intangible			
	Assets/ Capital Work-In-Progress		-64.47	
	(Increase)/Decreaseby sale/purchase in Non-Curren	t Investmer	-244.26	
	Interest Income		30.86	<u>)</u>
	Net Cash used in Investing activities			-277.87
	(3) CASH FLOW FROM FINANCING ACTIVITIES		1	
	Proceeds from/ (Repayment) of Long term Borrowin	ıgs	51.39)
	Proceeds from issue of share capital	Ĭ	1,692.60	D
	premium received		2,538.3	9
1	A MODE	ο π		

	Increase/(Decrease) in Short Term Borrowings Interest and Other Finance Costs paid	-48.57 (5.90)	
	Net Cash used in financing activities	4,227.	.90
"B"	Net increase in cash & Cash Equivalents	1,659.0	01
	Add: Cash and Cash equivalents at the Beginning of the Year 1.04.2024	42.	.82
"c"	Cash & Cash Equivalents at 30.09.2024	1,701.8	





AJOONI BIOTECH LIMITED

Regd. Office : D-118, Industrial Area, Phase-VII, Mohali-160055 (Pb.) Phone : 0172-5020758-69 Website : www.ajoonibiotech.com E-mail : ajooni.biotech@gmail.com / info@ajoonibiotech.com CIN: L85190PB2010PLC040162

Statement of Assets and Liabilities For the Year ended on 30th SEPTEMBER 2024

PARTICULARS	20TH OPD 202 -	in Rs. (Lakhs)
I. ASSETS	30TH SEP 2024	31ST MARCH 2024
(1) Non - Current Assets		
a) Property, Plant and Equipment	004.45	
b) Capital Work In Progress	994.17	1,031.89
c) Investment Property	106.60	92.45
d) Goodwill		.
e) Other Intangible Assets		-
f) Intangible Assets Under Development		
g) Biological Assets other than Bearer Plants		-
h) Financial Assets		. .
(1) Investments		
(2) Trade Receivables	433.91	213.63
(3) Loans		=
(4) Other Financial Assets		-
i) Deffered Tax Asset (net)		
j) Other Non Current Asset	32.33	31.22
	200.00	150.00
<u>Current Assets</u>		
a) Inventories	1 (0(17	
b) Financial Assets	1,696.17	1,536.73
(1) Investments		
(2) Trade Receivables	2,333.43	
(3) Cash & Cash Equivalent	1,701.83	1,295.94
(4) Bank Balances other than (iii) above	1,701.03	42.82
(5) Loans	1,386.88	057 40
(6) Other Financial Asset	4,000,00	351.42
c) Current Tax Assets (net)		0.00
d) Other Current Asset	24.32	-
	44.32	5.93



	TOTAL	8,909.64	4,752.04
II E	QUITY AND LIABILITIES		· ·
(1)	Equity		
	a)Equity Share Capital	2 4 4 4 05	
	b) Other Equity	3,444.87	1,752.27
	, <u>1</u> ,	5,167.57	2,518.51
(2)	Non-Current Liabilities		
	a) Financial Liabilities		
	(1) Borrowings	219.59	168.20
	(2) Trade Payables	and so it is a second sec	100.20
	(3) Other Financial Liabilties		
	b) Employee Benefit Obligations	13.04	11.99
	c) Deferred Tax Liability (net)		11.75
	d) Other Non Current Liability		
			-
<u>3)</u>	Current Liabilities		
	a) Financial Liabilities		
	(1) Borrowings	0.00	48.57
	(2) Trade Payables	0.00	158.45
	(3) Other Financial Liabilities	0.00	150,45
	b) Employee Benefit Obligations	0.95	1.05
	c) Other Current Liabilities	44.55	5.48
	d) Current tax liabilities (Net)	19.07	87.50
		15.07	87.50
	TOTAL	8,909.64	4,752.04
	6	310TE	
	Place : Mohali	For Ajooni Biotech Li	mited
	Date : 13.11.2024	OHALTING 10+ 1+h	
	A	Jasjot Singh	
		* Managing Director	
		DIN: 01937631	



SCO 65-B (1st Floor) City Heart, Kharar Chandigarh Road, Kharar, SAS Nagar Mohali-140301 Mobile : 98154 50065 Email : nkgargcal@yahoo?cb.in

Limited Review Report Ref. No.

Review Report to Board of Directors of M/s Ajooni Biotech Limited.

We have reviewed the accompanying statement of unaudited financial results of M/s Ajooni Biotech Limited having Regd. office at D-118, Industrial Area, Phase-VII, Mohali Punjab-160055. for the period ended 30th September, 2024.(the Statement) attached herewith , being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and disclosure requirements) regulations 2015 (as amended), Including relevant circulars issued by the Securities and Exchange Board of India (SEBI) from time to Time.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly,

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For NARINDER KUMAR AND COMPANY DER KUMAR & C Chartered Accountants S.C.O charved 65-B (1st Floor (HARINDER KUMAR GARG) City Heart Kharar-Cha Kharar, Mo rh Road PARTNER FRN-0030737N Charlered Accountar M.NO-080287

Date:-13.11.2024 UDIN:- 24080287BKBLOC9555